2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.
Investor Overview
Latest News
Neovasc's Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference
> read full release
Programs and Events
Corporate Overview Presentation
Fred Colen, CEO, Neovasc, Inc.
from the Global Investment Conference
Monday, Sept. 9, 2019
Neovasc Featured at the MicroCap Rodeo Conference
Listen to the webcast of Fred Colen’s presentation to the first-annual gathering of microcap companies and investors in Austin, Texas by clicking here >
Financial Report Archives
2019 Financial Reports
News Release Archives
2019 News Releases
Share Information
Auditor
Grant Thornton LLP, Vancouver, BC
Legal Counsel
Blakes LLP, Vancouver, BC
Transfer Agent
Computershare, Vancouver, BC
Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com
To automatically receive news updates